BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 14561086)

  • 1. Thermal denaturation: a method to rank slow binding, high-affinity P38alpha MAP kinase inhibitors.
    Kroe RR; Regan J; Proto A; Peet GW; Roy T; Landro LD; Fuschetto NG; Pargellis CA; Ingraham RH
    J Med Chem; 2003 Oct; 46(22):4669-75. PubMed ID: 14561086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Catalysis and function of the p38 alpha.MK2a signaling complex.
    Lukas SM; Kroe RR; Wildeson J; Peet GW; Frego L; Davidson W; Ingraham RH; Pargellis CA; Labadia ME; Werneburg BG
    Biochemistry; 2004 Aug; 43(31):9950-60. PubMed ID: 15287722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and characterization of a substrate selective p38alpha inhibitor.
    Davidson W; Frego L; Peet GW; Kroe RR; Labadia ME; Lukas SM; Snow RJ; Jakes S; Grygon CA; Pargellis C; Werneburg BG
    Biochemistry; 2004 Sep; 43(37):11658-71. PubMed ID: 15362850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-activity relationships of the p38alpha MAP kinase inhibitor 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)naph- thalen-1-yl]urea (BIRB 796).
    Regan J; Capolino A; Cirillo PF; Gilmore T; Graham AG; Hickey E; Kroe RR; Madwed J; Moriak M; Nelson R; Pargellis CA; Swinamer A; Torcellini C; Tsang M; Moss N
    J Med Chem; 2003 Oct; 46(22):4676-86. PubMed ID: 14561087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein kinase inhibitors from the urea class.
    Dumas J
    Curr Opin Drug Discov Devel; 2002 Sep; 5(5):718-27. PubMed ID: 12630292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A detailed comparison of current docking and scoring methods on systems of pharmaceutical relevance.
    Perola E; Walters WP; Charifson PS
    Proteins; 2004 Aug; 56(2):235-49. PubMed ID: 15211508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Affinity classification of kinase inhibitors by mass spectrometric methods and validation using standard IC(50) measurements.
    Jecklin MC; Touboul D; Jain R; Toole EN; Tallarico J; Drueckes P; Ramage P; Zenobi R
    Anal Chem; 2009 Jan; 81(1):408-19. PubMed ID: 19067573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural basis for the high-affinity binding of pyrrolotriazine inhibitors of p38 MAP kinase.
    Sack JS; Kish KF; Pokross M; Xie D; Duke GJ; Tredup JA; Kiefer SE; Newitt JA
    Acta Crystallogr D Biol Crystallogr; 2008 Jul; D64(Pt 7):705-10. PubMed ID: 18566506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hybrid-designed inhibitors of p38 MAP kinase utilizing N-arylpyridazinones.
    Colletti SL; Frie JL; Dixon EC; Singh SB; Choi BK; Scapin G; Fitzgerald CE; Kumar S; Nichols EA; O'Keefe SJ; O'Neill EA; Porter G; Samuel K; Schmatz DM; Schwartz CD; Shoop WL; Thompson CM; Thompson JE; Wang R; Woods A; Zaller DM; Doherty JB
    J Med Chem; 2003 Jan; 46(3):349-52. PubMed ID: 12540232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutagenesis of p38alpha MAP kinase establishes key roles of Phe169 in function and structural dynamics and reveals a novel DFG-OUT state.
    Bukhtiyarova M; Karpusas M; Northrop K; Namboodiri HV; Springman EB
    Biochemistry; 2007 May; 46(19):5687-96. PubMed ID: 17441692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of the distal C162S mutation on the energetics of drug binding to p38alpha MAP kinase.
    Todorova NA; Doseeva V; Ramprakash J; Schwarz FP
    Arch Biochem Biophys; 2008 Jan; 469(2):232-42. PubMed ID: 17996717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of 4-azaindoles as inhibitors of p38 MAP kinase.
    Trejo A; Arzeno H; Browner M; Chanda S; Cheng S; Comer DD; Dalrymple SA; Dunten P; Lafargue J; Lovejoy B; Freire-Moar J; Lim J; Mcintosh J; Miller J; Papp E; Reuter D; Roberts R; Sanpablo F; Saunders J; Song K; Villasenor A; Warren SD; Welch M; Weller P; Whiteley PE; Zeng L; Goldstein DM
    J Med Chem; 2003 Oct; 46(22):4702-13. PubMed ID: 14561090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two classes of p38alpha MAP kinase inhibitors having a common diphenylether core but exhibiting divergent binding modes.
    Michelotti EL; Moffett KK; Nguyen D; Kelly MJ; Shetty R; Chai X; Northrop K; Namboodiri V; Campbell B; Flynn GA; Fujimoto T; Hollinger FP; Bukhtiyarova M; Springman EB; Karpusas M
    Bioorg Med Chem Lett; 2005 Dec; 15(23):5274-9. PubMed ID: 16169718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implications for selectivity of 3,4-diarylquinolinones as p38alphaMAP kinase inhibitors.
    Peifer C; Urich R; Schattel V; Abadleh M; Röttig M; Kohlbacher O; Laufer S
    Bioorg Med Chem Lett; 2008 Feb; 18(4):1431-5. PubMed ID: 18207396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benzothiazole based inhibitors of p38alpha MAP kinase.
    Liu C; Lin J; Pitt S; Zhang RF; Sack JS; Kiefer SE; Kish K; Doweyko AM; Zhang H; Marathe PH; Trzaskos J; Mckinnon M; Dodd JH; Barrish JC; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1874-9. PubMed ID: 18296051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and structure-activity relationship of aminobenzophenones. A novel class of p38 MAP kinase inhibitors with high antiinflammatory activity.
    Ottosen ER; Sørensen MD; Björkling F; Skak-Nielsen T; Fjording MS; Aaes H; Binderup L
    J Med Chem; 2003 Dec; 46(26):5651-62. PubMed ID: 14667219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benzimidazolone p38 inhibitors.
    Dombroski MA; Letavic MA; McClure KF; Barberia JT; Carty TJ; Cortina SR; Csiki C; Dipesa AJ; Elliott NC; Gabel CA; Jordan CK; Labasi JM; Martin WH; Peese KM; Stock IA; Svensson L; Sweeney FJ; Yu CH
    Bioorg Med Chem Lett; 2004 Feb; 14(4):919-23. PubMed ID: 15012994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Computational sampling of a cryptic drug binding site in a protein receptor: explicit solvent molecular dynamics and inhibitor docking to p38 MAP kinase.
    Frembgen-Kesner T; Elcock AH
    J Mol Biol; 2006 May; 359(1):202-14. PubMed ID: 16616932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site.
    Pargellis C; Tong L; Churchill L; Cirillo PF; Gilmore T; Graham AG; Grob PM; Hickey ER; Moss N; Pav S; Regan J
    Nat Struct Biol; 2002 Apr; 9(4):268-72. PubMed ID: 11896401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3,4-Diaryl-isoxazoles and -imidazoles as potent dual inhibitors of p38alpha mitogen activated protein kinase and casein kinase 1delta.
    Peifer C; Abadleh M; Bischof J; Hauser D; Schattel V; Hirner H; Knippschild U; Laufer S
    J Med Chem; 2009 Dec; 52(23):7618-30. PubMed ID: 19591487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.